Jesy Nelson calls plan to test newborns for deadly muscle condition a 'victory'

Jesy Nelson, the former Little Mix member turned solo artist, has thrown her support behind a public health milestone. England's National Health Service will now screen all newborns for Spinal Muscular Atrophy using a heel prick test, marking a major expansion of the newborn screening program.

SMA is a rare genetic disorder that attacks motor neurons, progressively weakening muscles and potentially causing severe disability or death. Early detection transforms outcomes dramatically. Treatment exists, but timing matters intensely. Caught early, intervention can prevent the worst progression.

Nelson's backing carries weight beyond typical celebrity endorsement. She's become a vocal advocate for SMA awareness, lending her platform to push for expanded testing and access to treatment. Her involvement reflects growing momentum in the rare disease community to prioritize early detection over waiting for symptoms to emerge.

The heel prick test itself is routine. Midwives collect a small blood sample from newborns within days of birth, the same procedure used to screen for other conditions including sickle cell disease and cystic fibrosis. Adding SMA to this panel costs little but catches cases that would otherwise go undiagnosed until irreversible damage occurs.

This screening rollout addresses a treatment access gap. Effective therapies like nusinersen and gene therapy exist but only work optimally in early stages. Many families currently miss the window for treatment because SMA isn't diagnosed until symptoms become obvious, sometimes too late for maximum benefit.

The move aligns England with several other countries that have already implemented universal SMA screening. Public health officials argue the test's low cost and high potential impact justify the expansion, especially given that early treatment can fundamentally alter a child's quality of life and lifespan.

Nelson's vocal support underscores how celebrity advocacy increasingly shapes health policy conversations and public awareness around rare genetic conditions.